Larimar Therapeutics Files Q1 2025 10-Q
Ticker: LRMR · Form: 10-Q · Filed: Apr 30, 2025 · CIK: 1374690
| Field | Detail |
|---|---|
| Company | Larimar Therapeutics, Inc. (LRMR) |
| Form Type | 10-Q |
| Filed Date | Apr 30, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceutical, financials, quarterly-report
Related Tickers: LRMR
TL;DR
Larimar (LRMR) filed its Q1 2025 10-Q. Financials and ops update.
AI Summary
Larimar Therapeutics, Inc. filed a 10-Q for the period ending March 31, 2025. The company, formerly known as Zafgen, Inc., is in the pharmaceutical preparations industry. Key financial data and operational details for the first quarter of 2025 are presented in this filing.
Why It Matters
This filing provides investors with an update on Larimar Therapeutics' financial health and operational status for the first quarter of 2025, crucial for understanding the company's performance and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Larimar Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 6,284 P3Y — General and Administrative Expense (This likely represents a significant expense category for the quarter.)
- 2025-01-01 to 2025-03-31 — Reporting Period (This is the period covered by the 10-Q filing.)
Key Players & Entities
- Larimar Therapeutics, Inc. (company) — Filer
- ZAFGEN, INC. (company) — Former company name
- 20250331 (date) — Reporting period end date
- 20250430 (date) — Filing date
- 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
FAQ
What were the primary drivers of Larimar Therapeutics' financial performance in Q1 2025?
The filing details financial statements for the period ending March 31, 2025, which would outline revenue, expenses, and net income/loss, but specific drivers are not detailed in the provided header information.
Has Larimar Therapeutics announced any significant clinical trial updates or regulatory milestones in Q1 2025?
The provided text does not contain specific details on clinical trial updates or regulatory milestones for Q1 2025.
What is the current cash position of Larimar Therapeutics as of March 31, 2025?
The filing covers the period ending March 31, 2025, and would include balance sheet information detailing cash and cash equivalents, but this specific figure is not in the header.
Are there any new risks or changes in existing risks disclosed in this 10-Q filing?
The filing is a standard 10-Q, which typically includes risk factor updates, but the specific changes are not detailed in the provided header information.
What is the company's outlook for the remainder of 2025 based on this filing?
While the 10-Q provides a snapshot of the first quarter, forward-looking statements and management's outlook for the rest of 2025 would be found within the full report, not just the header.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on April 30, 2025 regarding Larimar Therapeutics, Inc. (LRMR).